ClinicalTrials.gg
CompletedNCT02188745POLLYUpdated Sep 25, 2026Results posted

ER Reactivation Therapy for Breast Cancer

A Phase 2 interventional study of 17B-estradiol and Letrozole in Metastatic Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center. Completed at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Dartmouth-Hitchcock Medical Center · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Updated Sep 25, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing estradiol in Breast Neoplasms — 1 open to participants now, 4 under way, none of them phase 3. Estradiol · Breast Neoplasms.

Enrollment
5th of 10
20 · median 20
Started
2016
the only one that year
Phase 2
9 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Dartmouth-Hitchcock Medical Center

Among the 10 studies testing estradiol in Breast Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 9 in phase 2, and was the 7th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 10 studies testing estradiol in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing estradiol in Breast Neoplasms, or all of them as a file.
02

Study summary

Before anti-estrogens such as tamoxifen were developed to treat estrogen receptor (ER)-positive breast cancer, high-dose estrogen therapies were used. This seems counterintuitive since anti-estrogens block ER function, while estrogens increase ER function, but these therapies are effective to similar extents for the treatment of metastatic ER+ breast cancer. Estrogen therapies are most effective against cancers that develop resistance to anti-estrogens, likely because such cancers have adapted to grow without ER function, and restoring ER function (with estrogen) is damaging to the cancer cells. In some patients with ER+ breast cancer that becomes resistant to anti-estrogens, treatment with the estrogen 17B-estradiol induces tumor response. Furthermore, when 17B-estradiol-sensitive tumors eventually become resistant to 17B-estradiol, switching back to anti-estrogen therapy is often effective. These observations suggest that cancers can alternate between anti-estrogen-sensitive and 17B-estradiol-sensitive states. The investigators hypothesize that treatment with alternating 17B-estradiol / anti-estrogen therapies on a defined 8-week / 16-week schedule will more effectively prevent cancer growth than continuous treatment with either type of therapy in patients with metastatic anti-estrogen-resistant ER+ breast cancer.

Read the detailed description

Metastatic breast cancer is rarely cured by current therapies. ER+ breast cancers ultimately become resistant to all available anti-estrogens. Response rates to estrogens are similar to those of anti-estrogens in the metastatic setting. Given that ER+ breast cancers are often responsive to anti-estrogens and estrogens, alternating anti-estrogen/estrogen therapies may be more effective than continuous treatment with either type of agent. Anecdotal evidence indicates that such a strategy of alternating therapies is effective in some patients. Preclinical evidence suggests that anti-estrogen-resistant ER+ breast cancers are sensitized to the anti-tumor effects of estrogens. Such cells harbor subpopulations that can ultimately regain the ability to grow in the presence of estrogens, and revert to their anti-estrogen-sensitive state. The investigators will formally test whether alternating 17B-estradiol/anti-estrogen therapies is effective for the management of anti-estrogen-resistant metastatic ER+/HER2- breast cancer, and to identify molecular biomarkers that predict tumor response to 1) 17B-estradiol and 2) alternating 17B-estradiol/anti-estrogen therapies. If successful, this study would present a novel strategy to manage metastatic ER+/HER2- breast cancer by pre-emptively switching therapies prior to disease progression.

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • metastatic
  • locally advanced
  • ER+
  • Estrogen therapy
  • Estradiol therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women ≥18 years of age with clinical stage IV ER+/- breast cancer, or with locally recurrent ER+/HER2- disease not amenable to therapy for curative intent.
  2. Patient must have been treated with an anti-estrogen at any time in their disease history. Combination regimens that include an anti-estrogen and any biologic, or targeted therapy, are permitted (e.g., any CDK inhibitor, everolimus, or any other novel biologics), and are considered to be a single hormonal therapy based regimen.

    • Any number of prior lines of anti-estrogen (i.e., hormonal) therapy is permissible.
    • One for advanced/ disease is permissible.
  3. Histologic documentation of ER strongly+/HER2- breast cancer by core needle , fine needle aspiration, incisional biopsy, or surgical biopsy of ≥1 site(s) of metastatic or locally advanced disease performed as standard of care within the past 4 months for assessment of eligibility for study participation (except as noted below in c/d/e).

    1. ER strongly+ status defined as ER staining by immunohistochemistry in ≥50% of malignant cell nuclei with an intensity ≥2+ on a scale of 0-3+. These criteria are equivalent to an Allred score ≥6.
    2. HER2-negative status is defined as immunohistochemistry score of 0-1+, or with a FISH ratio of \<2 if IHC is 2+ or if IHC has not been done (as per ASCO/CAP definitions). In cases of borderline or equivocal HER2 status, eligibility will be determined by the PI.
    3. Archived tumor specimens: Excess tumor tissue must be available for research purposes. This will include tumor tissue sufficient to make ≥10 five-micron sections; more tumor tissue is preferred.

      Freshly acquired tumor specimens: As part of a clinically indicated biopsy procedure, an additional 1-3 cores or tissue fragments will be obtained by core needle or surgical biopsy for research purposes and FFPE.

    4. Patients with bone-only metastatic disease with a history of ER+/HER2- breast cancer are eligible, and bone biopsy is not required, providing their primary cancer is consistent with the above-described ER and HER2 criteria.
    5. Patients with non-bone metastatic disease in whom a safe and accurate biopsy of recurrent/metastatic disease cannot be readily obtained are also eligible, providing their primary cancer is consistent with the above-described ER and HER2 criteria.
  4. Patient must be a candidate for treatment with 17B-estradiol and an aromatase inhibitor.
  5. If the most recent therapy was in the setting, the recurrence-free interval (time from initiation of adjuvant anti-estrogen therapy to clinical evidence of disease recurrence) must have been ≥2 years.

    If the most recent therapy was in the advanced/metastatic setting, the progression-free interval must have been ≥3 months (except in the case of hormonal therapies).

  6. Patient must be based on either a history of an oophorectomy, or ≥1 year of amenorrhea. An elevated serum gonadotropin level and estradiol level in the postmenopausal range (as locally defined) can be used to confirm menopausal status in a subject with \<1 year of amenorrhea.
  7. Baseline radiographic staging, including specifically either PET/CT, or CT (CAP) and bone scan.
  8. Patient must be capable and willing to provide informed written consent for study participation.
  9. The following laboratory values must be confirmed for eligibility within 28 days prior to initiation of study therapy:

Hematology panel

  • > 9 g/dL
  • white blood cell (WBC) count (≥ 2,000/uL)
  • count ≥ 75,000/uL Serum biochemistry/metabolic panel
  • creatinine ≤ 1.5 x (ULN)
  • total ≤ 1.5 x upper limits of normal (ULN)
  • and AST ≤ 3.0 x upper limits of normal (ULN) For patients with liver metastasis: \< 5 x upper limits of normal (ULN)

Exclusion criteria

Exclusion Criteria:

  1. Treatment with fulvestrant within 16 weeks prior to study enrollment.
  2. Any other concurrent systemic anti-cancer treatments, including conventional chemotherapeutic agents and biological agents, during the study period.

    Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.

  3. Any cancer therapy in the last 3 weeks.
  4. Known CNS disease, unless clinically stable for ≥ 3 months.
  5. History of any of the following:

    • deep venous thrombosis
    • pulmonary embolism
    • stroke
    • acute myocardial infarction
    • congestive heart failure
    • previous not treated with curative intent, or with an estimated recurrence risk ≥30%
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Alternating Therapy

    Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred. 17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day. Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day. Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day. Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day.

    Drug: 17B-estradiol · Drug: Letrozole · Drug: Anastrozole · Drug: Exemestane

Interventions

  • DrugEstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Anti-estrogen

    Also known as: aromatase inhibitor

  • Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

    Also known as: Letrozole (Aromatase inhibitor)

  • Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

    Also known as: Aromatase inhibitor

  • Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.

    Also known as: Aromatase inhibitor

06

What researchers measure

Primary outcomes

  1. Clinical Benefit

    Determine the rate of clinical benefit from alternating 17B-estradiol/aromatase. Clinical benefit is defined as complete response, partial response or stable disease at 24 weeks per RECIST criteria.

    Time frame: 24 weeks

Secondary outcomes

  1. Objective Response Rate

    Determine the objective response rate of patients treated with 17B-estradiol therapy for 8 weeks. Objective Response is defined as complete response + partial response as per RECIST criteria; the proportion of patients experiencing objective response on 17B-estradiol will be calculated to determine objective response rate.

    Time frame: 8 weeks

  2. Progression-free Survival

    Determine the progression-free survival from alternating 17B-estradiol/aromatase inhibitor therapy in patients with advanced ER+ breast cancer. Progression-free survival is defined as the time period from the start of a treatment until the time of cancer progression or death from any cause. Cancer progression will be determined as per RECIST criteria.

    Time frame: 12 Months

  3. Adverse Event Profiles

    Determine the adverse event profiles of 17B-estradiol and aromatase inhibitors in this patient population. Adverse events will be recorded as Grade 1, 2, 3, or 4. Incidences will be compared within patients over time.

    Time frame: 12 Months

  4. Predictive Tumor Genetic Lesions

    Determine whether specific tumor genetic lesions in ESR1 are predictive of response to 17B-estradiol and/or subsequent aromatase inhibitor therapies. The rates of clinical benefit from 17B-estradiol and/or subsequent AI therapy will be reported.

    Time frame: 12 Months

07

Results

Posted Sep 25, 2026

Participant flow

20 were recruited

Participant flow — Overall Study
MilestoneAlternating Therapy
Started20
Completed19
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryClinical Benefit

Determine the rate of clinical benefit from alternating 17B-estradiol/aromatase. Clinical benefit is defined as complete response, partial response or stable disease at 24 weeks per RECIST criteria.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Clinical Benefit
ParticipantsAlternating Therapy
Partial Response3
Stable Disease5
Disease Progression11
SecondaryObjective Response Rate

Determine the objective response rate of patients treated with 17B-estradiol therapy for 8 weeks. Objective Response is defined as complete response + partial response as per RECIST criteria; the proportion of patients experiencing objective response on 17B-estradiol will be calculated to determine objective response rate.

Time frame:
8 weeks
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsAlternating Therapy
Objective Response Rate15.8
SecondaryProgression-free Survival

Determine the progression-free survival from alternating 17B-estradiol/aromatase inhibitor therapy in patients with advanced ER+ breast cancer. Progression-free survival is defined as the time period from the start of a treatment until the time of cancer progression or death from any cause. Cancer progression will be determined as per RECIST criteria.

Time frame:
12 Months
Reported as:
Median · weeks
Progression-free Survival
weeksAlternating Therapy
Progression-free Survival16.9 (8.9 to 23)
SecondaryAdverse Event Profiles

Determine the adverse event profiles of 17B-estradiol and aromatase inhibitors in this patient population. Adverse events will be recorded as Grade 1, 2, 3, or 4. Incidences will be compared within patients over time.

Time frame:
12 Months
Reported as:
Count of participants · Participants
Adverse Event Profiles
ParticipantsAlternating Therapy
Adverse Event Profiles1
SecondaryPredictive Tumor Genetic Lesions

Determine whether specific tumor genetic lesions in ESR1 are predictive of response to 17B-estradiol and/or subsequent aromatase inhibitor therapies. The rates of clinical benefit from 17B-estradiol and/or subsequent AI therapy will be reported.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Predictive Tumor Genetic Lesions
percentage of participantsAlternating Therapy
Predictive Tumor Genetic Lesions42.1

Adverse events

Collected over Post 30 days of last study treatment up to 12 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alternating Therapy0/20 (0%)0/20 (0%)1/20 (5%)
Most frequent other events
Most frequent other events
EventAlternating Therapy
ThromboembolismVascular disorders1/20
Patient #10 discontinued treatment before completing cycle 1 due to mood changes and irritability.Social circumstances1/20

Baseline characteristics

Age, Customized
Age, Customized(years)Alternating Therapy
Median Age of Participants61 ± 61
Sex: Female, Male
Sex: Female, Male(Participants)Alternating Therapy
Female20
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alternating Therapy
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White20
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Alternating Therapy
United States — Massachusetts1
United States — New Hampshire13
United States — Minnesota6
08

Study locations

3 sites
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jan 2024, 93 months.

Results were first posted in Sep 2026, 2 years 8 months after primary completion.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 93 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jul 14, 2014
StartActual
Mar 11, 2016
Primary completionActual
Jan 5, 2024
CompletionActual
Jul 5, 2024
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Enrollment
19→20
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedClinical benefitBenefitTime frame: 12 Months → 24 weeks
Sep 25, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedObjective response rateResponse RateTime frame: 8 weeks
  • EditedProgression-free survivalSurvivalTime frame: 12 Months
  • EditedAdverse event profilesEvent ProfilesTime frame: 12 Months
  • EditedPredictive tumor genetic lesionsTumor Genetic LesionsTime frame: 12 Months
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Enrollment 19→20
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedClinical benefitBenefitTime frame: 12 Months → 24 weeks
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedObjective response rateResponse RateTime frame: 8 weeks
    • EditedProgression-free survivalSurvivalTime frame: 12 Months
    • EditedAdverse event profilesEvent ProfilesTime frame: 12 Months
    • EditedPredictive tumor genetic lesionsTumor Genetic LesionsTime frame: 12 Months
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02188745
Responsible party
Mary D Chamberlin (Associate Professor of Medicine, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Jul 14, 2014
Start date
Mar 11, 2016
Primary completion
Jan 5, 2024
Completion
Jul 5, 2024
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Mary Chamberlin, MD
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Letrozole · Anastrozole · Exemestane

Start the discussion